However, the BRCA1 and p53 mutations suggests that it is a Type II high-grade serous carcinoma of the SET (Solid, pseudo-endometrioid and transitional cell carcinoma-like morphology) subtype [29–31]. This evidence concerns the gene TP53 and transitional cell carcinoma.